Pneumococcal Vaccines Market Analysis 2026

Factors Affecting the Growth of the Pneumococcal Vaccines Market

The rising cases of pneumonia are directly driving the demand for pneumococcal vaccines in the market.

Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae, as called pneumococcus. There are more than 100 subtypes and most of the subtypes can cause disease, but only a few produce the majority of invasive pneumococcal infections. Pneumonia is the single largest infectious cause of death in children worldwide. It causes more than a million hospitalizations and more than 50,000 deaths each year. (Source: https://www.lung.org/lung-health-diseases/lung-disease-lookup/pneumonia/five-facts-you-should-know) 

Around 4,000 cases of pneumococcal bacteremia occur every year in the United States. Bacteremia is the most common clinical presentation among children aged two years and younger, accounting for 70% of invasive disease in this group. Additionally, there are an estimated 2,000 cases of pneumococcal meningitis every year. Considering the criticality, pneumococcal disease is a serious disease that causes much sickness and death. Around, 30,300 cases and 3,250 deaths from invasive pneumococcal diseases are estimated to have occurred in the United States in 2019.
(Source: https://www.immunize.org/wp-content/uploads/catg.d/p4213.pdf) 

Furthermore, pneumonia accounts for around 14% of all deaths of children under 5 years old, killing nearly 740,180 children in 2019. (Source: https://www.who.int/news-room/fact-sheets/detail/pneumonia) 

Certain medical concerns associated with the pneumococcal vaccine may restrict the Pneumococcal Vaccines Market growth. 

Normally, most people who get a pneumococcal vaccine do not have any serious problems with it; however, with any medicines and vaccines, chances of being caught to certain side effects are always there. The side effects tend to be mild and go away on their own within a few days; however, some serious reactions might be possible. 

Mild problems related to PCV15, PCV20, or PPSV23 can include Redness, swelling, pain, or tenderness where the shot was given, Fever or chills, Loss of appetite, Fussiness, Feeling tired, Headache, Muscle ache, or joint pain. These symptoms may lead people to avoid the vaccination, resulting in the restriction in the market growth. (Source: https://www.cdc.gov/vaccines/vpd/pneumo/public/index.html) 

The most common side effects from pneumococcal vaccines are mild and last for 1 or 2 days. The chances of getting severe allergic reactions are very rare.; however, such independent risk factors can restrict the market growth for pneumococcal vaccines.

An innovative financial mechanism by the Pneumococcal Advance Market Commitment can be considered as an opportunity for vaccine makers to produce vaccines at affordable prices. 

Each year, pneumococcal disease takes the lives of half a million children under five years of age, making it the leading vaccine-preventable cause of death among young children. The most effective estimate to prevent these deaths is to ensure access to effective, safe, and affordable vaccines. To make this happen, a pneumococcal Advance Market Commitment (AMC) has been designed to protect children against pneumococcal disease.

This financial commitment offers an innovative funding mechanism with the help of donor commitments, that can benefit vaccine makers to produce suitable and affordable vaccines for the world’s poorest countries accelerating the global roll-out of a vaccine against the world’s leading cause of child deaths. These countries will then be able to plan for immunisation programmes knowing that vaccines will be available rapidly, in the quantities they need and at affordable prices. As a result, the PCV AMC pilot likely was successful at driving higher coverage of PCV than has been seen with other antigens. This increased coverage led to more lives saved.

Such practices can help the producers to reach and expand their market even in the least developed and poor countries, leading to a rise in market growth. 
(Source: https://www.gavi.org/investing-gavi/innovative-financing/pneumococcal-amc/about-pneumococcal-amc) 

How did the COVID–19 Impact the Pneumococcal Vaccines Market?

The outbreak of coronavirus disease resulted in a decline in global vaccination efforts due to the burden on health systems and community resistance to epidemic control measures. The situation was further worsened by the lockdowns of receiving countries where airports were closed. The outbreak not only collapsed the airline industry, but the vaccine shipments and other critical deliveries were also heavily impacted due to a dramatic decline in the available flights. However, vaccines were still recommended for vulnerable populations to prevent severe pneumonia conditions. Some other studies also reported that during the coronavirus disease 2019 pandemic, routine immunization activities were at risk of disruption due to the burden on the health system, reduced need for vaccination owing to physical distancing requirements, and community resistance. 

The COVID-19 pandemic did impact the world; however, it also resulted in increased awareness of the importance of vaccination among women, and adults. COVID-19-induced immunological dysfunction is still a high-risk factor for pneumococcal illness. COVID-19 is regarded as a key risk factor for pneumococcal pneumonia and invasive pneumococcal disease. As a result, pneumococcal vaccination became more important during the COVID-19 pandemic and the market started growing significantly.

Recent Developments

•    3rd April 2024: Manipal Hospitals announced its collaboration with Pfizer, an American multinational pharmaceutical and biotechnology corporation, to improve patient care and advocate for adult vaccination. 
(Source: https://www.thehindu.com/news/national/andhra-pradesh/manipal-hospitals-collaborates-with-pfizer-to-improve-patient-care/article68025462.ece) 
•    20th December 2023: The U.S. Food and Drug Administration (FDA) accepted Merck’s new biologics license application (BLA). The vaccine is intended to prevent invasive pneumococcal disease and pneumococcal pneumonia in adults.
(Source: https://www.pharmaceutical-technology.com/news/fda-merck-pneumococcal-vaccine/?cf-view) 
•    27th July 2023: Merck, known as MSD announced positive topline results from two Phase 3 trials evaluating V116, the company’s investigational 21-valent pneumococcal conjugate vaccine in vaccine-naïve and previously vaccinated individuals.
(Source: https://www.merck.com/news/merck-announces-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-for-adults-met-key-immunogenicity-and-safety-endpoints-in-two-phase-3-trials/) 
•    27th April 2023: Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20® (20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD).
(Source: https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20r-pfizers-20-valent-pneumococcal)
•    16th August 2022: GSK plc announced that it has completed the acquisition of Affinivax, Inc., a clinical-stage biopharmaceutical company based in Cambridge. Affinivax has pioneered the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines.
(Source: https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-affinivax-inc/) 
•    12th August 2022: Pfizer announced positive top-line results from its pivotal U.S. Phase 3 study of 20-valent pneumococcal conjugate vaccine in infants.
(Source: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study-20) 

With the help of the above study about the Pneumococcal Vaccines Market, it can be concluded that the market for Pneumococcal Vaccine worldwide is expected to develop significantly shortly. From the report, one can understand and infer the market dynamics, segmentations, status and trends, and key players in the market. It provides data regarding various topics such as market dimensions, prevailing trends, competitive landscape, and the outlook for prospective expansion. This allows the reader to understand and access reliable data about the market and industry.

Frequently Asked Questions (FAQs)